Q1 26 EPS
$4.08
BEAT +0.99%
Est. $4.04
Q1 26 Revenue
$85.93B
MISS 0.28%
Est. $86.17B
vs S&P Since Q1 26
-21.7%
TRAILING MARKET
COR -14.7% vs S&P +7.0%
Market Reaction
Did COR Beat Earnings? Q1 2026 Results
Cencora posted a mixed but broadly encouraging fiscal first quarter for 2026, edging past earnings expectations while falling just short on the top line. Adjusted diluted EPS of $4.08 beat the $4.04 consensus by 0.99%, rising 9.4% year-over-year on t… Read more Cencora posted a mixed but broadly encouraging fiscal first quarter for 2026, edging past earnings expectations while falling just short on the top line. Adjusted diluted EPS of $4.08 beat the $4.04 consensus by 0.99%, rising 9.4% year-over-year on the strength of its U.S. Healthcare Solutions segment, where the January 2025 acquisition of Retina Consultants of America expanded gross margins and lifted segment operating income 21.0%. Revenue of $85.93 billion grew 5.5% year-over-year but came in 0.28% below the $86.17 billion consensus estimate, held back in part by the loss of a grocery and an oncology distribution account. The quarter's most consequential development may prove forward-looking: Cencora completed its OneOncology acquisition and promptly raised its fiscal 2026 adjusted operating income growth guidance to 11.5%-13.5%, up sharply from a prior range of 8%-10%, while reaffirming full-year adjusted diluted EPS guidance of $17.45 to $17.75. JPMorgan's recent decision to increase its Cencora stake by 21.3% suggests institutional confidence in the company's specialty-focused growth strategy remains intact.
Key Takeaways
- • Overall market growth driven by unit volume growth in specialty products to health systems and physician practices
- • Increased sales of GLP-1 class products labeled for diabetes and/or weight loss
- • January 2025 acquisition of Retina Consultants of America expanding gross profit margins
- • Growth in European distribution business driving International Healthcare Solutions revenue
- • LIFO credit of $77.6 million in the current quarter vs. $7.3 million in prior year quarter
- • $86.8 million litigation settlement credit offsetting operating expenses
COR YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
COR Revenue by Segment
With YoY comparisons, source: SEC Filings
“Cencora began fiscal 2026 by delivering strong financial performance and advancing our strategy through the acquisition of OneOncology.”
— Robert P. Mauch, Q1 2026 Earnings Press Release
COR Earnings Trends
COR vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
COR EPS Trend
Earnings per share: estimate vs actual
COR Revenue Trend
Quarterly revenue: estimate vs actual
COR Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $4.73 | $4.75 | +0.48% | $78.36B | -3.31% |
| Q1 26 BEAT | $4.04 | $4.08 | +0.99% | $85.93B | -0.28% |
| Q4 25 BEAT FY | $3.79 | $3.84 | +1.44% | $83.73B | +0.40% |
| FY Full Year | $15.94 | $16.00 | +0.36% | $321.33B | +0.11% |
| Q3 25 BEAT | $3.84 | $4.00 | +4.23% | $80.66B | +0.68% |
| Q2 25 BEAT | $4.10 | $4.42 | +7.92% | $75.45B | -0.46% |